Drug Database · Clinicians

Factor viii inhibitor bypassing activity

Brands (1) FeibaShow all

Blood coagulation factors PH FDA category

Rx · Prescription drug2 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • ) powder for solution for infusion: 500 Units/10 mL (50 Units/mL, 1000 U/20 mL (50 U/mL

Registered products in the Philippines

2 products registered with the Food and Drug Administration (FDA) Philippines list Factor viii inhibitor bypassing activity as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Factor viii inhibitor bypassing activity
Package insert
FeibaFactor VIII Inhibitor Bypassing Activity
1000 U/20 mL (50 U/mL) Powder for Solution for Infusion (IV)500, 1000, and 2500 units (U) per vial supplied with a diluent in a vial containing steril water for injection
Rx
Baxter AGAustria
Takeda Healthcare Philippines Inc.
BR-1443
Jun 19, 2028
Feiba: Factor VIII Inhibitor Bypassing Activity
500 Units/10 mL (50 Units/mL) Powder for Solution for Infusion (IV)Packaging: Each box contains: Type I clear and colorless glass vial with grey butyl rubber stopper and aluminum crimp cap with polypropylene flip-off disk (drug product) + Type I clear glass vial with bromobutyl rubber stopper and aluminum seal plastic flip-off cap (Sterile Water for Injection as diluent) + Twin set butterfly needle 22G (Venofix) and cannula 20G (Sterican) + Sterile needleless transfer device for reconstitution (Baxter II Hi-Flow) + Disposable syringe with luer lock (Omnifix).
Rx
Baxter AGAustria
Takeda Healthcare Philippines Inc.
BR-1438
Feb 8, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Formulary and pricing (Philippines)

Formulary and coverage

Philippine National FormularyListed as Factor VIII Inhibitor Bypassing Activity
PNF listingSolution for infusion (IV), 500 IU/10 mL
PNF listingSolution for infusion (IV), 1,000 IU/10 mL
PNF listingSolution for infusion (IV), 2,500 units/50 mL
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  2. PhilHealth Advisory No. 2025-0060, Electronic PNF EML (ePNF) as of September 19, 2025, annex of added medicines; DOH-DC No. 2025-0341 (included 2025-08-11); https://www.philhealth.gov.ph/advisories/2025/PA2025-0060_v1.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .